Summary

Biotech’s rebound broadened after the April 7 bottom, but the panel saw no proof that generalists have returned. XBI gained about 15% and small-/mid-cap tracker BBC 30%, while remaining down roughly 12% and 24% for the year; some microcaps rallied 40–50%. Josh Schimmer still found it “hard to call them green shoots,” whereas Paul Matteis saw specialists moving from defense toward “a little bit more offense.”
Marty Makary’s FDA could materially increase rare-disease and early-stage asset optionality if its promised flexibility becomes practice. He questioned why bringing a drug to market takes 10 years, discussed one randomized trial followed by EHR-based surveillance, conditional rare-disease approval on a plausible mechanism without randomization, and less animal testing. Tim Opler predicted near-term approvals from “relatively small data sets” when results are decisive, while John Maraganore stressed that speed must preserve scientific standards and political independence.
FDA execution remains a “tale of two cities,” with disruption and improving morale visible simultaneously. Some companies reported delays tied to staffing and reorganization, yet one protocol amendment received a response within 24 hours. Tim relayed former CDER associate director Naomi Loeb’s account that the five-day office mandate drove reviewers away, but said the switch to three days and Makary’s arrival were rapidly improving morale; John remained “net-net optimistic” while awaiting evidence through the rest of the year.
Pharma tariffs remain less a settled policy than leverage over domestic manufacturing and global drug pricing. Tim characterized the threat as atmospheric and part of a “game of poker” intended to drive onshoring and narrow U.S.-versus-Germany price gaps. His key downside was access: manufacturers might raise prices outside America, hurting countries less able to pay.
Cobenfy’s failed adjunctive schizophrenia study lowered one commercial scenario without destroying the real-world combination thesis. The signal was modest, and Citi cut peak-sales expectations from $3.4 billion to $2.8 billion, although Alzheimer’s psychosis could lift them to $5 billion; William Blair estimated about $3.7 billion without that upside. Because roughly one-third of patients already receive two overlapping atypical antipsychotics, Paul argued clinicians will still ask, “What other choice do you have?” after multiple failures.
uniQure’s breakthrough designation revived the broader gene-therapy flexibility trade after Peter Marks’s departure. Its Huntington’s program showed little placebo separation at one year but roughly 80% slowing versus natural history at two years; three-year data and the registrational statistical plan are next. Paul viewed the post-Marks designation as evidence that the alignment resides deeper within CBER, making favorable pathways at other rare-disease companies more credible.
The short-selling debate exposed biotech’s deeper capital-allocation problem rather than a convenient culprit. Stifel found specialist long holdings fell in 2024 while fund count rose and aggregate AUM stayed roughly flat, implying greater short exposure; long/short and multistrategy funds generally held or gained assets while long-only funds lost them. Josh called below-cash balances largely “prepaid expenses” and argued biotech remains “some winners and a lot of losers” because it consumes capital inefficiently and rarely returns it.
Academic pressure could become a long-term biotech competitiveness risk. John Maraganore warned that government actions toward Harvard and reported actions toward the New England Journal of Medicine could affect academic funding, peer review, U.S. scientific excellence, and competition with China. Tim said proposed NIH cuts had not happened but could harm the innovation funnel; the group debated foreign funding and antisemitism while agreeing that institutions central to biomedical research must be preserved.
The survival playbook is fewer programs, decisive catalysts, resilient supply chains, and visible leadership. John urged CEOs to preserve cash and fund only the work most likely to move patient and enterprise value; Paul warned that companies may get only “one or two chances” to release genuinely de-risking data. Tim’s jarring specimen was a single-asset company, backed by five established VCs, budgeting $55 million merely to reach an IND.

Deep dive

1. The rally broadened before the biotech thesis truly repaired

From the April 7 low, XBI rose about 15% and BBC about 30%, although they remained down roughly 12% and 24% year to date. A rumored $3.5 billion Merck KGaA–SpringWorks deal offered only a slight premium and remained below SpringWorks’ February valuation.
Josh’s pushback — worth keeping: XBI was still struggling to recover its highs from earlier this year, last year, or even five years earlier. Persistent pressure on biopharmaceutical spending constrains returns and makes the index “a very good gauge” of generalists’ continuing disinterest.
Paul saw a narrower but meaningful change in positioning: attention had expanded beyond five or six de-risked, commercial, or no-financing-overhang names into early-stage microcaps, some up 40–50%. Specialists appeared to be playing “less defense” and “a little bit more offense,” even if generalists were not buying the next gene-therapy story.

2. Makary’s flexibility could become the sector’s most important rerating mechanism

Daphne said Makary questioned why it takes 10 years to bring a drug to market and discussed using one randomized controlled trial followed by intensive postmarketing surveillance based on EHR data. He called V-safe and VAERS unreliable because they rely on self-reporting. For rare conditions, a plausible mechanism might support conditional approval without a randomized study, subject to continued health-record monitoring.
The modernization agenda extended to organ-on-chip systems, predictive in-vitro modeling, AI-assisted review, and phasing out some animal-testing requirements for monoclonal antibodies and other drugs. Makary also proposed replacing pharma representatives on advisory committees with patients or family representatives and dismantling internal “silos and fiefdoms.”
John described current performance as a “tale of two cities”: some companies face delays, while another received feedback on a protocol amendment within 24 hours. A delayed Vanda CRL appeal was explicitly attributed by the FDA to staffing, reorganization, and disruption. Daphne also noted that Makary claimed cuts spared reviewers, scientists, and inspectors, though that did not fit some CEOs’ reports; her own n-of-one interactions were functioning well and meeting timelines.
Tim relayed former CDER associate director Naomi Loeb’s account that the five-day office requirement helped drive reviewers away; her final weekly accomplishment was, “I found another job.” After Marty said employees could attend three days a week, Tim said morale was changing rapidly and predicted relatively small but decisive rare-disease datasets could win approvals within “the next two or three weeks.” John’s condition: flexibility must remain science-based and carefully managed.

3. Tariffs threaten access even if their main purpose is negotiation

Tim regarded pharmaceutical tariffs as a potentially severe but still “atmospheric” threat: leverage to force onshoring and narrow the price difference between the same medicine in America and Germany. He feared manufacturers would respond by increasing overseas prices, worsening access in countries less wealthy than the United States.
Big Pharma had already announced expanded U.S. manufacturing investments, while industry groups advocated non-tariff incentives and companies adjusted earnings or revenue outlooks. John noted that Alnylam’s largely domestic API manufacturing and proximity to profitability would help, but globally sourced raw materials still leave exposure.
The geopolitical response predates this tariff cycle: John said companies such as Alnylam, Vertex, and Regeneron were investing in more secure domestic supply chains after Russia, Ukraine, and other disruptions. Separately, the executive order addressing the IRA’s “pill penalty” was viewed positively because it might address the nine-versus-13-year issue, including the nine years for small molecules.

4. Cobenfy stumbled, while Spravato keeps validating difficult psychiatric delivery

Paul’s psychedelic framing began with Spravato: an every-other-week antidepressant involving dissociation and monitored administration, with only “okay” efficacy after succeeding in half its studies. Yet roughly 50,000 people are on it, and J&J has made substantial investments in the necessary infrastructure, evidence that cumbersome neuropsychiatric medicines can still achieve meaningful adoption.
Physicians, including specialists building dedicated psychedelic centers, were preparing to use the emerging class despite stigma and operational differences among products. That mattered because several psychedelic companies traded near cash or roughly two times cash, while investors still questioned the class.
Bristol’s trial combining Cobenfy with another antipsychotic failed, with only a modest overall signal. Excluding patients taking one atypical antipsychotic produced a larger effect, but not enough to erase the disappointment; Daphne noted the trial was also needed to establish combination safety before tapering the older drug.
Paul nevertheless kept the core commercial case intact: about one-third of schizophrenia patients already take two atypical antipsychotics with overlapping mechanisms and adverse effects. Cobenfy lacks the desired combination label, but difficult patients who fail two, three, or four medicines will likely still receive it adjunctively in practice.

5. Data maturity, not the first headline, drives the gene-therapy and bladder trades

uniQure’s Huntington’s study showed little drug-placebo separation at one year, potentially because the therapy was weak or because patients progress too slowly for early discrimination. The two-year comparison with natural history suggested roughly 80% disease slowing, with three-year results and the formal registrational analysis still ahead.
Paul treated breakthrough designation after Peter Marks’s departure as the critical signal: the FDA viewed the data as promising, while uniQure’s favorable alignment appeared rooted within CBER rather than dependent on one official. That raised confidence in rare-disease flexibility extending to other gene-therapy programs.
At AUA, Josh expected mature back-to-back presentations to clarify a year-long comparison between J&J’s bladder-inserted TAR-200 and CG Oncology’s cretostimogene in non-muscle-invasive bladder cancer. TAR-200’s apparent complete-response advantage, close to 10% or somewhat lower, had narrowed as the J&J data matured, though it still appeared to retain an advantage. The larger clinical point was that patients need multiple options before invasive bladder-resection surgery.

6. Short sellers are responding to biotech’s structure, not creating it

Stifel’s 2024 review separated registered advisers’ total AUM — including cash, longs, shorts, and non-biotech investments — from their long biotech holdings. Specialist fund count increased and AUM was roughly unchanged while long biotech holdings declined, suggesting specialists became substantially more short.
Strategy explained the asset flows: long/short and multistrategy funds generally maintained or gained AUM, while long-only funds lost assets. Catalio, 8VC, SilverArc, Darwin, Forbion, Sofinnova Partners, and Patient Square were among the gainers, supporting Tim’s conclusion that specialist managers entered 2025 in better aggregate shape than sector sentiment implied.
Cantor’s Eric Schmidt argued that short pressure can destroy already-fragile companies. Josh’s rebuttal was categorical: hedge funds are doing their job, and biotech cannot select only the convenient parts of capital markets; the industry’s deeper problems are repeated failure, inefficient capital consumption, patent cliffs, the IRA, China, and few durable business models.
Daphne added nuance: wall-crossed PIPEs can suppress post-data appreciation and further alienate generalists, while shorts can create powerful covering rallies after genuinely positive news. They may manipulate illiquid stocks, but for a well-performing company they can also keep management focused on downside risk.

7. Academic conflict is now a biotech competitiveness issue

John deliberately separated the merits of government actions toward Harvard and reported actions toward the New England Journal of Medicine from their industry consequences. Academic research remains biotech’s “top of the funnel,” so funding disruption, peer-review constraints, or limits on scientific freedom could damage U.S. competitiveness and give China a longer-term advantage. He did not expect an immediate impact on biotech companies per se.
Tim pointed to Boston’s Harvard–MIT ecosystem and the Bay Area’s Berkeley–UCSF–Stanford cluster as “ground zero” for biotech innovation. Through Antonio Gramsci’s framework, he interpreted pressure on academia as an attempt at cultural and political control, while hoping it would recede like earlier rhetoric around Greenland or annexing Canada. He cautioned that proposed NIH cuts had not happened yet, but could profoundly harm the industry.
Daphne’s counterpoint was that institutions also accept hundreds of millions of dollars from Qatar and large sums from governments including China, often with limited transparency, potentially shaping ideology. Universities therefore must address government concerns and antisemitism while preserving academic freedom; they are not entirely free of outside influence.
Josh cited Harvard’s own legal filing as acknowledging severe antisemitism and incomplete compliance, questioning whether Jewish students felt protected. He contrasted $6 billion of continuing annual government funding, an additional $2 billion withdrawn, and a $50 billion endowment; the group’s eventual consensus was to protect minority students without decimating institutions central to biomedical science.

8. CEOs must preserve the option to survive before pursuing the option to expand

John’s first lesson was human rather than financial: turbulent markets test how CEOs and other leaders “show up” for their teams, remain patient, focus on the business, and make an impact. “Leadership needs to shine” precisely when uncertainty is hardest to absorb.
Strategically, he urged balance-sheet preservation and concentration on the few activities that most increase patient and enterprise value. Aspirational programs may need shelving or partnership financing; he was “not a big fan of spinouts,” but expected Darwinian attrition to leave a more focused, experienced industry.
Paul warned development-stage companies to release data only when it answers a key investment question and materially changes probability of success. Trickling out one or two merely “promising” patients can become a negative catalyst when investors expect a financing on the back of it: companies may receive only “one or two chances” to command attention.
Tim argued China’s rise should force far greater U.S. and European efficiency. His example was a one-molecule company with a known target and five respected venture backers budgeting $55 million to get to an IND — evidence that, despite years of market pressure, “there’s still a lot of adjustment that needs to happen.”

Market Overview, April 29, 2025 The Software Crisis Behind America's Infrastructure